Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft
作者： Gewen Tan , Hideki Kasuya , Tevfik Tolga Sahin , Kazuo Yamamura , Zhiwen Wu
DOI: 10.1002/IJC.29163
关键词:
摘要: Breast cancer is one of the most common and feared cancers faced by women. The prognosis patients with advanced or recurrent breast remains poor despite refinements in multimodality therapies involving chemotherapeutic hormonal agents. Multimodal therapy more specific effective strategy urgently needed. oncolytic herpes simplex virus (HSV) has potential to become a new treatment option because its broad host range tumor selective viral distribution. Bevacizumab monoclonal antibody against VEGFA, which inhibits angiogenesis therefore growth. Our approach enhance antitumor effect HSV combine HF10 bevacizumab cancer. results showed that enhanced distribution as well hypoxia expanded population apoptotic cells induced synergistic effect. expected be promising agent combination anticancer treatment.
sci-hub.se 参考文章(49)
Gregg L. Semenza, Peter H. Roth, Guang L. Wang, Hon Ming Fang, Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. Journal of Biological Chemistry. ,vol. 269, pp. 23757- 23763 ,(1994) , 10.1016/S0021-9258(17)31580-6
Chris Boshoff, Kaposi's sarcoma - Coupling herpesvirus to angiogenesis Nature. ,vol. 391, pp. 24- 25 ,(1998) , 10.1038/34054
Bernd Gerber, Mathias Freund, Toralf Reimer, Recurrent Breast Cancer Deutsches Aerzteblatt Online. ,vol. 107, pp. 85- 91 ,(2010) , 10.3238/ARZTEBL.2010.0085
Yves Boucher, Rakesh K. Jain, Microvascular Pressure Is the Principal Driving Force for Interstitial Hypertension in Solid Tumors: Implications for Vascular Collapse Cancer Research. ,vol. 52, pp. 5110- 5114 ,(1992)
Yves Boucher, Rakesh K. Jain, Michael Leunig, Tumor Angiogenesis and Interstitial Hypertension Cancer Research. ,vol. 56, pp. 4264- 4266 ,(1996)
Y Nishiyama, H Kimura, T Daikoku, Complementary lethal invasion of the central nervous system by nonneuroinvasive herpes simplex virus types 1 and 2. Journal of Virology. ,vol. 65, pp. 4520- 4524 ,(1991) , 10.1128/JVI.65.8.4520-4524.1991
J. Nemunaitis, F. Khuri, I. Ganly, J. Arseneau, M. Posner, E. Vokes, J. Kuhn, T. McCarty, S. Landers, A. Blackburn, L. Romel, B. Randlev, S. Kaye, D. Kirn, Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer Journal of Clinical Oncology. ,vol. 19, pp. 289- 298 ,(2001) , 10.1200/JCO.2001.19.2.289
Akihiro Nawa, ChenHong Luo, Lumin Zhang, Yoko Ushjima, Daisuke Ishida, Maki Kamakura, Yasushi Fujimoto, Fumi Goshima, Fumitaka Kikkawa, Yukihiro Nishiyama, Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy. Current Gene Therapy. ,vol. 8, pp. 208- 221 ,(2008) , 10.2174/156652308784746422
Mark A Currier, Francis K Eshun, Allyson Sholl, Artur Chernoguz, Kelly Crawford, Senad Divanovic, Louis Boon, William F Goins, Jason S Frischer, Margaret H Collins, Jennifer L Leddon, William H Baird, Amy Haseley, Keri A Streby, Pin-Yi Wang, Brett W Hendrickson, Rolf A Brekken, Balveen Kaur, David Hildeman, Timothy P Cripe, VEGF Blockade Enables Oncolytic Cancer Virotherapy in Part by Modulating Intratumoral Myeloid Cells Molecular Therapy. ,vol. 21, pp. 1014- 1023 ,(2013) , 10.1038/MT.2013.39
Hideto Kimata, Tsuneo Imai, Toyone Kikumori, Osamu Teshigahara, Tetsuro Nagasaka, Fumi Goshima, Yukihiro Nishiyama, Akimasa Nakao, Pilot Study of Oncolytic Viral Therapy Using Mutant Herpes Simplex Virus (HF10) Against Recurrent Metastatic Breast Cancer Annals of Surgical Oncology. ,vol. 13, pp. 1078- 1084 ,(2006) , 10.1245/ASO.2006.08.035